drugset / Trial / NCT00641693

Assess the Efficacy and Safety of Rhinocort Aqua

NCT00641693

Phase 2 Completed 650 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5 years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and stuffy noses.

Timeline

Start
2004-04
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 16 mg Intranasal
Subject Budesonide Small molecule 32 mg Intranasal
Subject Budesonide Small molecule 64 mg Intranasal

Indications